Goldman Sachs Initiates Natera at Neutral, $245 Target
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
nateragoldman-sachs
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Goldman Sachs announced on 05 June 2026 that it has initiated research coverage of Natera Inc. with a Neutral rating and a 12-month price target of $245. The initiation by a major bulge-bracket investment bank places a formal valuation benchmark on the liquid biopsy and reproductive health diagnostics company. The call comes as Natera's stock trades at $123.85, a figure representing a premium to broader market indices but a steep discount to Goldman's stated target. The $245 target implies a potential upside of approximately 98% from current levels.
Goldman's coverage initiation arrives at a critical juncture for the liquid biopsy sector, which has faced significant valuation compression over the past 18 months. The last major Wall Street initiation in the space occurred in late 2024, when Morgan Stanley assigned an Overweight rating to Guardant Health with a target 30% above its trading price at the time. Since then, rising interest rates have pressured the present value of long-dated earnings for growth-stage diagnostic companies.
The current macro backdrop features a 10-year Treasury yield hovering near 4.3%, a level that historically dampens investor appetite for high-multiple, cash-burning technology and healthcare names. Sector-wide, the iShares U.S. Medical Devices ETF (IHI) is down 5% year-to-date, underperforming the broader S&P 500. The catalyst for Goldman's entry now likely stems from Natera's evolving path to profitability and its expanding reimbursement coverage for key tests like Signatera, which monitors cancer recurrence.
Analyst scrutiny has intensified following Natera's first-quarter 2026 earnings report, which showed revenue growth decelerating to 15% year-over-year from over 20% in prior quarters. The company's guidance for narrowing operating losses in the second half of the year has created a tangible milestone for fundamental analysts to assess. Goldman's decision to publish formal research provides institutional investors a standardized framework for modeling the stock's risk-reward profile ahead of these anticipated improvements.
Goldman Sachs' $245 price target for Natera stands 97.8% above the stock's price of $123.85 as of 08:00 UTC today. This large gap between current price and target valuation highlights the divergent views on the company's future cash flows. Natera's current market capitalization is approximately $14.8 billion, based on its latest reported share count.
The stock has gained a modest 0.54% in the trading session following the news. This muted reaction contrasts with the more significant 2.63% gain seen in Goldman Sachs' own shares (GS), which traded at $1,092.61. The disparity suggests the market views the initiation as a standard research event rather than a transformative catalyst for Natera.
| Metric | Natera (NTRA) | Goldman Sachs (GS) |
|---|---|---|
| Current Price | $123.85 | $1,092.61 |
| Price Target | $245 | N/A |
| Implied Upside | +97.8% | N/A |
| Today's Change | +0.54% | +2.63% |
Natera's valuation multiples remain elevated relative to more established diagnostics peers. The company trades at a price-to-sales ratio of approximately 7.5x, compared to an industry median of around 3.5x for small-to-mid cap diagnostics firms. This premium reflects the market's pricing of Natera's superior growth profile and its dominant position in the minimal residual disease monitoring segment.
The Neutral rating suggests Goldman Sachs sees Natera as fairly valued at present levels when weighing its growth opportunities against execution and market risks. This view creates a formal anchor for other institutional desks, potentially reducing volatility as large funds benchmark their own models against Goldman's assumptions. The primary second-order effect is likely on Natera's direct competitors.
Guardant Health (GH) and Exact Sciences (EXAS) could see incremental selling pressure as capital allocators compare valuations across the liquid biopsy landscape. Guardant, which focuses on early cancer detection, trades at a similar growth-adjusted multiple, while Exact Sciences, with its established colorectal cancer screening business, trades at a lower multiple but with slower growth. A re-rating of Natera based on improved fundamentals would likely lift the entire peer group.
A key limitation to the bullish $245 target is Natera's ongoing cash burn. The company is not expected to reach GAAP profitability until 2027 at the earliest, making it sensitive to shifts in capital market conditions. Should interest rates move higher than currently forecast, the present value of its future earnings would decline, pressuring the stock irrespective of operational execution. Current positioning data indicates hedge funds remain net short Natera, betting on further multiple compression, while long-only healthcare funds are accumulating shares on dips, viewing the current price as an entry point for a 3-5 year hold.
The immediate catalyst for Natera will be its second-quarter 2026 earnings report, scheduled for late July or early August. Investors will scrutinize the revenue growth rate, gross margin trends, and any updates to full-year guidance for billable test volumes. Management commentary on reimbursement progress for Signatera in additional cancer types will be critical for validating the long-term total addressable market.
Technical levels to watch include the 50-day moving average near $118, which has acted as recent support. A sustained break above the $130 resistance level, last tested in April 2026, could signal a shift in momentum and attract trend-following buyers. Conversely, a drop below $115 would likely trigger stop-loss orders and test the conviction of long-term holders.
The broader sector outlook hinges on the upcoming J.P. Morgan Healthcare Conference in January 2027, where management teams provide annual strategic updates. Regulatory decisions from the Centers for Medicare & Medicaid Services on national coverage determinations for liquid biopsy tests will also dictate the sector's revenue trajectory through the end of the decade. Any acceleration in FDA approvals for companion diagnostic claims would be a material positive for the entire industry.
A Neutral rating indicates Goldman Sachs' analysts believe Natera's current stock price fairly reflects its near-term prospects and risks. It is not a recommendation to buy or sell. The accompanying $245 price target, however, suggests they see significant long-term value if the company executes on its growth and profitability plans. For investors, this initiation provides a detailed, institutional-grade financial model against which to compare their own assumptions, adding liquidity and analyst coverage to the stock.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.